Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

The long non-coding RNA ANRASSF1 in the regulation of alternative protein-coding transcripts RASSF1A and RASSF1C in human breast cancer cells: implications to epigenetic therapy.

Calanca N, Paschoal AP, Munhoz ÉP, Galindo LT, Barbosa BM, Caldeira JRF, Oliveira RA, Cavalli LR, Rogatto SR, Rainho CA.

Epigenetics. 2019 Aug;14(8):741-750. doi: 10.1080/15592294.2019.1615355. Epub 2019 May 27.

PMID:
31062660
2.

Identification of novel biomarkers associated with poor patient outcomes in invasive breast carcinoma.

Canevari RA, Marchi FA, Domingues MA, de Andrade VP, Caldeira JR, Verjovski-Almeida S, Rogatto SR, Reis EM.

Tumour Biol. 2016 Oct;37(10):13855-13870. Epub 2016 Aug 2.

PMID:
27485113
3.

ATM down-regulation is associated with poor prognosis in sporadic breast carcinomas.

Bueno RC, Canevari RA, Villacis RA, Domingues MA, Caldeira JR, Rocha RM, Drigo SA, Rogatto SR.

Ann Oncol. 2014 Jan;25(1):69-75. doi: 10.1093/annonc/mdt421. Epub 2013 Nov 26.

4.

Absence of transforming growth factor-beta type II receptor is associated with poorer prognosis in HER2-negative breast tumours.

Paiva CE, Drigo SA, Rosa FE, Moraes Neto FA, Caldeira JR, Soares FA, Domingues MA, Rogatto SR.

Ann Oncol. 2010 Apr;21(4):734-40. doi: 10.1093/annonc/mdp518. Epub 2009 Nov 13.

5.

Gene expression profile of residual breast cancer after doxorubicin and cyclophosphamide neoadjuvant chemotherapy.

Koike Folgueira MA, Brentani H, Carraro DM, De Camargo Barros Filho M, Hirata Katayama ML, Santana de Abreu AP, Mantovani Barbosa E, De Oliveira CT, Patrão DF, Mota LD, Netto MM, Caldeira JR, Brentani MM.

Oncol Rep. 2009 Oct;22(4):805-13.

PMID:
19724859
6.

Quantitative real-time RT-PCR and chromogenic in situ hybridization: precise methods to detect HER-2 status in breast carcinoma.

Rosa FE, Silveira SM, Silveira CG, Bérgamo NA, Neto FA, Domingues MA, Soares FA, Caldeira JR, Rogatto SR.

BMC Cancer. 2009 Mar 23;9:90. doi: 10.1186/1471-2407-9-90.

7.

Evaluation of estrogen receptor alpha and beta and progesterone receptor expression and correlation with clinicopathologic factors and proliferative marker Ki-67 in breast cancers.

Rosa FE, Caldeira JR, Felipes J, Bertonha FB, Quevedo FC, Domingues MA, Moraes Neto FA, Rogatto SR.

Hum Pathol. 2008 May;39(5):720-30. doi: 10.1016/j.humpath.2007.09.019. Epub 2008 Jan 30.

PMID:
18234277
8.

Shorter CAG repeat in the AR gene is associated with atypical hyperplasia and breast carcinoma.

De Abreu FB, Pirolo LJ, Canevari Rde A, Rosa FE, Moraes Neto FA, Caldeira JR, Rainho CA, Rogatto SR.

Anticancer Res. 2007 Mar-Apr;27(2):1199-205.

9.

Gene expression profiling of clinical stages II and III breast cancer.

Folgueira MA, Brentani H, Katayama ML, Patrão DF, Carraro DM, Mourão Netto M, Barbosa EM, Caldeira JR, Abreu AP, Lyra EC, Kaiano JH, Mota LD, Campos AH, Maciel MS, Dellamano M, Caballero OL, Brentani MM.

Braz J Med Biol Res. 2006 Aug;39(8):1101-13.

10.

CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer.

Caldeira JR, Prando EC, Quevedo FC, Neto FA, Rainho CA, Rogatto SR.

BMC Cancer. 2006 Mar 2;6:48.

11.

Gene expression profile associated with response to doxorubicin-based therapy in breast cancer.

Folgueira MA, Carraro DM, Brentani H, Patrão DF, Barbosa EM, Netto MM, Caldeira JR, Katayama ML, Soares FA, Oliveira CT, Reis LF, Kaiano JH, Camargo LP, Vêncio RZ, Snitcovsky IM, Makdissi FB, e Silva PJ, Góes JC, Brentani MM.

Clin Cancer Res. 2005 Oct 15;11(20):7434-43.

12.

Comparative genomic hybridization detects novel amplifications in fibroadenomas of the breast.

Ojopi EP, Rogatto SR, Caldeira JR, Barbiéri-Neto J, Squire JA.

Genes Chromosomes Cancer. 2001 Jan;30(1):25-31.

PMID:
11107172

Supplemental Content

Loading ...
Support Center